SecBot SecBot
8-K ·Filed Feb 26, 2026

KYMR

Kymera Therapeutics, Inc.
MIXED
Impact 6/10
Horizonmonths Processed8mo ago SEC0001193125-26-073386
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

Monitor upcoming clinical data readouts for KT-621 in mid-2027 (atopic dermatitis) and late-2027 (asthma), and KT-579 data in 2H26. The increased R&D spend with declining collaboration revenue suggests the company is prioritizing pipeline advancement over near-term profitability.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$95.03
T+0 close · Feb 26, 2026 · via day close
Latest settled
−15.17%
T+60 · $80.61
Vs SPY
−22.92%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $95.03entry
  2. T+1 · 9mo ago −3.87%α −3.42% · $91.35
  3. T+5 · 9mo ago −12.11%α −10.98% · $83.52
  4. T+20 · 8mo ago −15.63%α −9.22% · $80.18
  5. T+60 · 6mo ago −15.17%α −22.92% · $80.61
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kymera Therapeutics reported financial results for Q4 and full year 2025, highlighted by a $692 million equity raise, pipeline progress including initiation of Phase 2b trials for KT-621 in atopic dermatitis and asthma, and a new Chief Development Officer appointment. The company ended 2025 with $1.6 billion in cash, providing runway into 2029.

Key Financial Metrics

Revenue
$39.2M
-16.7% YoY
EPS
$-3.69

Key Facts

  • Collaboration revenue declined 16.7% YoY to $39.2 million in 2025
  • R&D expenses increased 31.8% YoY to $316.6 million in 2025
  • Net loss widened to $311.4 million in 2025 from $223.9 million in 2024
  • Completed $692 million equity offering in December 2025
  • Cash balance of $1.6 billion as of December 31, 2025, providing runway into 2029
  • Initiated dosing in KT-579 Phase 1 trial and expanded KT-621 Phase 2b trials

Financial Impact

Revenue decreased by $7.9 million YoY while R&D spending increased by $76.4 million, resulting in a $87.5 million wider net loss. The $692 million capital raise significantly strengthened the balance sheet.

revenuer&d expensesnet losscash position

Risk Factors

  • Continuing reliance on external funding as collaboration revenue declines
  • High R&D spending with no near-term commercial products
  • Clinical trial risks for KT-621 and KT-579 programs

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-073386
Document: kymr-20260226.htm0001193125-26-073386
Document: 0001193125-26-073386-index-headers.html0001193125-26-073386
Document: 0001193125-26-073386-index.html0001193125-26-073386
Document: 0001193125-26-073386.txt0001193125-26-073386

Track record

37 reports on KYMR

Performance horizon

7 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +60.99% at T+60 after the Jun 8, 2026 report. 9 of 14 went positive at some point.

Filters
  1. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $127.09 Now $125.85 −0.98% settles Dec 2
  2. Oct 29, 202618d ago 8-K Neutral 5/10 No price data
  3. Oct 29, 202618d ago Press Release Bearish 5/10 Entry $122.60 Now $125.85 −2.65% settles Nov 27
  4. Oct 28, 202619d ago Press Release Neutral 5/10 Entry $122.60 Now $125.85 +2.65% settles Nov 27
  5. Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
  6. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
  7. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $110.85 Now $125.85 +13.53% settles Nov 20
  8. Aug 5, 202614w ago 8-K Bullish 6/10 Entry $105.48 to $118.63 Now $125.85 +19.31% ▲ +12.47% +13.07% vs SPY
  9. Jul 7, 202618w ago Insider Cluster Bearish 5/10 Entry $114.16 to $105.48 Now $125.85 −10.24% ▲ +7.60% +10.88% vs SPY
  10. Jul 2, 202619w ago Insider Cluster Bearish 5/10 Entry $114.76 to $100.31 Now $125.85 −9.66% ▲ +12.59% +13.44% vs SPY
Showing 10 of 37

US Market Status

Market Closed · Opens in 7h 25m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 26, 2026